Experts: Foreign Corrupt Practices Targeted by US

Pharmaceutical companies will face an increase in indictments as the U.S. Justice Department begins zeroing in on Foreign Corrupt Practices Act violations in the industry, Robert Bennett of the Bennett Law Firm said. Jennifer Bragg, a partner at Skadden, Arps, Slate, Meagher & Flom, said the risk of violations probably will be greater in countries with broad government-funded healthcare plans where physicians are paid by the government. A company’s financial relationships with those physicians can be interpreted as providing money to a government official, she said.
International Pharmaceutical Regulatory Monitor